Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Study Identifier:
TT30-PNH-002
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN1102
- Drug: ALXN1103
Date
Apr 2011 - Mar 2014
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN1102
- Drug: ALXN1103
Date
Apr 2011 - Mar 2014
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
The purpose of this research study is to understand the safety, pharmacokinetics and pharmacodynamics of a single dose of TT30 (ALXN1102 and ALXN1103 formulations) when given IV (through a vein) or SC (under the skin) to patients with PNH.
Trial Locations
Location
Status
Location
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Status
N/A
Location
Institute of Hematology and Blood Transfusion / Institut Hematologie a krevní transfuze
U nemocnice 1, Prague 2, Czech Republic, 128 08
Status
N/A
Location
Federico II University of Naples
Via Pansini 5, Naples, Italy, 80131
Status
N/A
Location
University Clinical Centre
Dębinki 7, Gdańsk, Poland, 80-952
Status
N/A
Location
King's College Hospital NHS Foundation Trust
Denmark Hill, London, United Kingdom, SE5 9RS UK
Status
N/A